Industry’s first quality solution to scale genAI adoption
India-based healthcare and life sciences technology provider and consultant CitiusTech has claimed to come up with what could be the industry’s first generative AI quality and trust solution.
Based on a press statement, the CitiusTech Gen AI Quality & Trust solution aims to help design, develop, integrate, monitor and facilitate quality and confidence in genAI applications in healthcare.
Using an automated design and decision-making framework, the software-based solution will provide “pre-packaged measures, automated output validation and monitoring” of the quality and reliability of gen AI solutions. It features more than 70 metrics and more than 25 methods in seven dimensions: accuracy, calibration, robustness, fairness, bias, toxicity and efficiency.
CitiusTech says its software offering fully integrates with existing MLOps, DataOps and quality management solutions.
WHY IT MATTERS
“Our Gen AI Quality & Trust Solution is the first systematic approach in healthcare to quantitatively measure, verify and monitor genAI solutions,” said Sridhar Turaga, CitiusTech’s SVP Data and Analytics. To date, he noted, “there are no established technology or cross-platform solutions that measure the quality and trust of genAI healthcare solutions end-to-end.”
CitiusTech also claims that more than 80% of genAI proofs of concept and initiatives their customers execute are delayed due to reliability and compliance issues and a lack of trust.
“We are seamlessly integrating this capability into all our solutions and projects so that our customers can confidently benefit from scaling genAI-powered solutions,” said CEO Rajan Kohli.
THE BIG TREND
The pace of genAI adoption in healthcare – at least in the Asia-Pacific, this year is expected to be slow as potential users remain uncertain about its safety and effectiveness.
“We will exercise the utmost caution in anything that has a direct impact on patient care. We know that technology can improve healthcare, but if it doesn’t function as expected, it can slow down healthcare systems, cost money and consumer loyalty, and worst of all impact patient outcomes,” Kota told Kubo, CEO of Ubie, previously Healthcare IT news. The Japanese IT startup recently integrated genAI into a new feature on its patient services platform, Ubie Medical Navi.
A recent notable adoption of genAI in the region is China Medical University Hospital in Taiwan, now using Google Cloud’s MedLM to develop tools for precise cancer treatment. In Singapore, national health technology agency Synapxe is currently working with Microsoft to build a GPT-based platform using Azure OpenAI Service to support the development of large language model-based apps. Singapore General Hospital has also shared its intention to leverage genAI to enhance the capabilities of its CARES-ML predictive tool for pre-surgery assessment.